Pharmacokinetics, safety, efficacy and immunogenicity of Adalimumab biosimilar ABP-501in rheumatoid arthritis and plaque psoriasis
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2021.
Prif Awdur: | Akter, Anika |
---|---|
Awduron Eraill: | Alam, Marzia |
Fformat: | Traethawd Ymchwil |
Iaith: | English |
Cyhoeddwyd: |
Brac University
2022
|
Pynciau: | |
Mynediad Ar-lein: | http://hdl.handle.net/10361/17039 |
Eitemau Tebyg
-
Biologics and Biosimilars as Treatment Options for Psoriasis
gan: Moya, Amena Khatun
Cyhoeddwyd: (2023) -
Importance of biologics in rheumatoid arthritis management
gan: Riyadh, S. M.
Cyhoeddwyd: (2022) -
TNF-α inhibitor-induced alopecia in psoriatic disease patients: a pharmacovigilance study
gan: Afroza, Halima
Cyhoeddwyd: (2024) -
Importance of biologically active agents over other therapies in Rheumatoid Arthritis- a review
gan: Mehreen, Elnaj
Cyhoeddwyd: (2021) -
A pharmacovigilance study on FDA approved interleukin inhibitor-associated alopecia in the treatment of psoriasis
gan: Islam, Nahidul
Cyhoeddwyd: (2023)